Vicarious Surgical Inc.

Vicarious Surgical Inc. , based in the US, specializes in developing advanced surgical robotic systems that enhance minimally invasive abdominal surgeries, providing innovative solutions for healthcare facilities and surgical teams. Vicarious Surgical Inc. was founded in 2014 and is headquartered in Waltham, US.

The company focuses on creating robotic systems for surgical applications. Adam Sachs serves as both the Founder and CEO. The company has completed a total of 8 deals to date, with the most recent funding round being PIPE, raising USD 27. 00 mn on September 9, 2021, which constitutes the total amount raised by the company.

Vicarious Surgical's core product offering is its advanced surgical robotic system designed for minimally invasive abdominal surgery. The system emphasizes access and visualization through a single port, requiring a small incision of 1. 5 cm, which is smaller than a dime. This innovative design allows for the insertion of a high-definition 3D camera and two robotic instruments, enhancing the surgeon's visibility and maneuverability during procedures.

The robotic system is equipped with 28 sensors per arm, replicating a surgeon’s natural upper body movements and facilitating precise instrument control. The Vicarious Surgical system aims to serve healthcare facilities and surgical teams focused on laparoscopic procedures across North America and Europe, where there is a growing demand for minimally invasive surgery solutions that minimize recovery time and complications. Vicarious Surgical generates revenue through its advanced surgical robotic system, which is designed for use in hospitals and surgical centers. The company’s business model revolves around direct sales to medical facilities, where surgical robots are integrated into their operating rooms.

Revenue is derived from the sale of the robotic systems, which includes proprietary software and instrumentation, alongside contracts for ongoing maintenance and support services. Additionally, the company is developing disposable instruments that will require smaller incisions, providing a competitive edge in the surgical robotics market. Pricing structures for these offerings are structured to support the healthcare institutions' budgets while ensuring accessibility to cutting-edge surgical technologies. The EBITDA for Vicarious Surgical in 2020 was USD -352,308.

Vicarious Surgical plans to leverage the recent PIPE funding of USD 27. 00 mn to further develop its robotic systems and enhance its product offerings. The company is focused on designing new products aimed at improving surgical outcomes and efficiency. Additionally, Vicarious Surgical intends to expand its market presence in North America and Europe, targeting more healthcare facilities and surgical centers to increase adoption of its innovative solutions.

The funding will also support ongoing research and development to introduce advanced features in its surgical robots.